Aaron Kantor, Frank Torti

Apr 10, 2008

Premium

The Immune Tolerance Institute this week said Aaron Kantor joined the company as chief scientific officer.

Prior to ITI, Kantor was executive director of cell and molecular biology for biomarker discovery sciences at Pharmaceutical Product Development, a contract research organization. Before that, he was manager for the rare cell program and cell depletion therapeutic program at AmCell.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

To See More Clearly

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

Which Fish Is Which?

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

The Suspects, Too

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

This Week in PNAS

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.